CV Therapeutics drug fails study |
|
|
|
Published
:
Tue, 06 Mar 2007 22:54
|
PALO ALTO, Calif. (AP) - Biopharmaceutical company CV Therapeutics Inc. said Tuesday its angina drug ranolazine, or Ranexa, showed no adverse trend in deaths or arrhythmias, but failed to meet its goal in a late stage study.The drug is already approved as a second-line treatment for chronic angina.The company said a Phase III clinical trial studying the drug for other uses as a treatment of coronary syndromes did not meet its primary study goal for effectiveness. But the safety results gathered from the study could support expansion of the drug into a first-line treatment.Full results will be released March 27 at the American College of Cardiology Scientific Session in New Orleans, the company said.Shares of CV Therapeutics rose 10 cents to close at $12.30 on the Nasdaq Stock Market.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
Print this Story
Barrier cites positive Hivenyl results 